A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children With Hemodynamically Significant Congenital Heart Disease
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Motavizumab (Primary) ; Palivizumab
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 25 Apr 2011 Results published in Pediatric Research.
- 24 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.